Hostname: page-component-7b7567c8c-tnkh4 Total loading time: 0 Render date: 2026-11-18T04:57:59.410Z Has data issue: false hasContentIssue false

Primary pulmonary hypertension: molecular basis and potential for therapy

Published online by Cambridge University Press:  08 March 2004

Nung Rudarakanchana
Affiliation:
Division of Respiratory Medicine, Department of Medicine, University of Cambridge, Box 157, Level 5, Addenbrooke' Hospital, Hills Road, Cambridge, CB2 2QQ, UK.
Nicholas W. Morrell
Affiliation:
Division of Respiratory Medicine, Department of Medicine, University of Cambridge, Box 157, Level 5, Addenbrooke' Hospital, Hills Road, Cambridge, CB2 2QQ, UK.
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the 'Save PDF' action button.

Primary pulmonary hypertension (PPH) is defined clinically by sustained elevation of pulmonary arterial pressure without a demonstrable cause, and is a progressive, often-fatal disease. PPH can be associated with ingestion of appetite suppressants, human immunodeficiency virus infection and certain autoimmune diseases. Familial PPH is known to account for 6% of all cases. Mutations in the gene encoding the bone morphogenetic protein (BMP) type II receptor have been identified in 72% of affected families and 26% of apparently sporadic cases. BMPs are members of the transforming growth factor β superfamily and affect intracellular signalling via Smads and mitogen-activated protein kinases. Evidence supports a ‘two-hit’ hypothesis in which PPH is triggered by accumulation of genetic and environmental insults in a susceptible individual. Elucidation of the precise molecular and cellular mechanisms underlying PPH will provide a powerful basis for the development of novel therapeutic strategies in the treatment of this devastating condition.

Information

Type
Review Article
Copyright
© Cambridge University Press 2004